BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. (10th September 2018)

• Record Type: Journal Article
• Authors: Ribero, Simone; Malavenda, Ottavia; Fava, Paolo; Astrua, Chiara; Marra, Elena; Osella-Abate, Simona; Sanlorenzo, Martina; Caliendo, Virginia; Fierro, Maria Teresa; Quaglino, Pietro
• Is Part Of: Future oncology. Volume 15:Number 2(2019)
• Page Start: 133
• Page End: 139
• Publication Date: 2018-09-10
• Subjects: BRAF inhibitors -- combination therapy -- MEK inhibitors -- melanoma; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0386
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: A survival benefit was demonstrated by dabrafenib + trametinib for metastatic BRAF -mutated melanoma patients. Best response is a strong prognostic marker for survival.Patients & methods: The specific features associated with complete response (CR) were evaluated.Results: A total of 15/66 patients achieved CR. Median size of lesions was 3 cm (range: 0.5–10). Using that value as cut-off, the CR rate was 39.3% in patients with smaller lesions and 10.5% in patients with bigger size (p = 0.006). The clinical features associated with CR were the number of metastatic sites and the largest diameter of the biggest metastatic site.Conclusion: The number of the metastases and the diameter of the largest metastatic site are associated with a higher CR rate.